Medically reviewed by Dr. Jyoti Rao, Consultant, Medical Affairs | Last reviewed July 2026
Key Takeaways
- For acoramidis in pregnancy, human data are insufficient to establish the safety of acoramidis during pregnancy.
- The approved ATTR-CM evidence base comes from an older adult population, not a pregnancy population.
- Animal findings support caution, but they don’t create evidence-based treatment recommendations for use during pregnancy.
The Starting Point Is an Evidence Gap
Acoramidis in pregnancy is best framed by what is not established. The label states that available data in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. That makes this a limited evidence base rather than a routine extension of standard ATTR-CM treatment logic, and it places the emphasis on individualized risk assessment rather than established treatment recommendations.
The Approved Evidence Base Is Demographically Distant from Pregnancy
The approved ATTR-CM evidence base is also demographically distant from pregnancy. The clinical study population described in the label was predominantly elderly, with a median age in the late seventies, which reinforces that the core efficacy and safety experience don’t answer pregnancy-specific questions. Therefore, these efficacy and safety data cannot be directly extrapolated to pregnant patients.
Animal Data Support Caution But Not a Treatment Algorithm
In the absence of adequate human data, available information is derived primarily from animal reproductive toxicity studies, but they still don’t create a pregnancy-use algorithm. The label describes reproductive-toxicology findings in rats and rabbits, including no embryofetal abnormalities at the exposures tested, increased pre-implantation loss in rabbits at a maternally toxic dose, and adverse pre- and postnatal findings in rats at high exposure. These findings should be interpreted with caution: acoramidis in pregnancy remains an individualized risk-assessment question in an unusual clinical scenario, not an evidence-based treatment recommendation. This article summarizes the available evidence and should not be considered a substitute for specialist maternal-fetal management.
Frequently Asked Questions
What does the acoramidis label say about pregnancy?
It states that available human data in pregnant women are insufficient to establish a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Available human data are insufficient to establish drug-associated risk during pregnancy.
Can the ATTR-CM trial evidence be applied to pregnancy?
No, not directly. The studied population was predominantly elderly, so the efficacy and safety experience doesn’t answer pregnancy-specific questions and shouldn’t be extrapolated directly to pregnant patients.
Do animal data settle how to use acoramidis in pregnancy?
No. Animal reproductive-toxicology findings support caution but don’t create evidence-based treatment recommendations during pregnancy. Any use is an individualized risk-assessment decision rather than a standard clinical practice.
Part of the Spotlight On ATTR-CM resource center.
References:
- ATTRUBY (acoramidis) prescribing information. U.S. Food and Drug Administration
This content is intended for healthcare professionals for educational purposes and is not a substitute for individual clinical judgment. It was developed with AI assistance and reviewed by a qualified healthcare professional for clinical accuracy prior to publication.